NCT04777916 Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
| NCT ID | NCT04777916 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Acute Leukemia French Association |
| Condition | Acute Myeloid Leukemia (AML) |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2022-04-14 |
| Primary Completion | 2032-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2022-04-14 with a primary completion date of 2032-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
During the last fifteen years, the landscape of AML diagnosis and therapeutical options has markedly evolved. Refined genetic and prognostic characterizations, together with new drug approvals and new allogeneic hematopoietic stem cell transplantation (HSCT) procedures, have increased patient journey diversity.
Eligibility Criteria
Inclusion Criteria: * Patient aged 18 years old or more * Patient with newly diagnosed previously untreated de novo, secondary or therapy-related AML * Patients with R/R de novo, secondary or therapy-related AML * Patient with Health insurance Exclusion Criteria: * Acute promyelocytic leukemia * AML which is not morphologically proven (patients with granulocytic sarcoma may be included) * For newly diagnosed AML: previous treatment of leukemia apart from hydroxyurea. Previous anti leukemia treatments are allowed if they were administered before the diagnosis of AML to treat a MDS, MPN, MPN/MDS or CML * Patient weighting less than 50 kgs * Opposition of the patient to participate to this non-interventional study More specific eligibility criteria might be requested to enter some study modules
Contact & Investigator
Hervé DOMBRET, PD-Prof
STUDY CHAIR
Acute Leukemia French Association
Frequently Asked Questions
Who can join the NCT04777916 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Myeloid Leukemia (AML). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04777916 currently recruiting?
Yes, NCT04777916 is actively recruiting participants. Contact the research team at karine.cellilebras@alfa-leukemia.org for enrollment information.
Where is the NCT04777916 trial being conducted?
This trial is being conducted at Amiens, France, Argenteuil, France, Bobigny, France, Caen, France and 11 additional locations.
Who is sponsoring the NCT04777916 clinical trial?
NCT04777916 is sponsored by Acute Leukemia French Association. The principal investigator is Hervé DOMBRET, PD-Prof at Acute Leukemia French Association. The trial plans to enroll 5,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.